Li Y, Kowdley KV

Idioma: Ingles.
Referencias bibliográficas: 16
Paginas: 272-274
Archivo PDF: 61.04 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

2. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, et al. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.

3. Maeda S, Kamata H, Luo J-L, Leffert H, Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-90.

4. Elsharkawy AM, Mann DA. Nuclear factor-κβ and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007; 46: 590-7.

5. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-12.

6. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. STAT3 is necessary for proliferation and survival in colon cancer– initiating cells. Cancer Res 2011; 71: 7226-37.

7. Lee H, Deng J, Xin H, Liu Y, Pardoll D, Yu H. A Requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κβ in tumors. Cancer Res 2011; 71: 3772-80.

8. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, et al. Hepatocyte IKK-β/NF-κβ inhibits tumor promotion and progression by preventing oxidative stressdriven STAT3 activation. Cancer Cell 2010; 17: 286-97.

9. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, et al. Ubiquitous activation of Ras and JAK/ STAT pathways in human HCC. Gastroenterology 2006; 130: 1117-28.

10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.

11. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147: 1233-47.

12. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, Ji L, Minna JD, et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 2011; 71: 3658-68.

13. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493-506.

14. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, et al. Phase I trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in advanced cancer. Mol Ther 2011 (In press).

15. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375: 1896-905.

16. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, et al. RNA-based gene therapy for HIV with lentiviral vector–modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36ra43.